1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > In Vitro Diagnostics Market Trends

Global Regulatory Overview For Companion Diagnostics Market

  • April 2014
  • 51 pages
  • Frost & Sullivan
Report ID: 2097974

Summary

Table of Contents

This study aims to cover the regulatory outlook and the diagnostics and drug approval process in the US, Europe, India, China, Japan and Brazil. Comparative analysis enables competitors to understand various regulatory hurdles and to position their products in pipeline better and plan for costs. Comparative analysis also enables an understanding of which geographies are hard to penetrate. Understanding regional barriers and the timeline taken for the evaluation process will help IVD and pharmaceutical companies choose an appropriate partner for their companion diagnostic product development.


Executive Summary

With the advent of personalized medicine and more patient-based care, there has been an
increase in the activity of partnerships between pharmaceutical companies and in vitro
diagnostic companies.

For a companion diagnostic manufacturer, it becomes necessary to understand the
reimbursement landscape and the regulatory landscape in order to plan its costs based on
the expected timeline of product release.

The United States follows the most organized regulatory pathway for companion
diagnostics, and many countries are trying to replicate the same regulatory pathway. The
United States has been enforcing the co-development of drugs and diagnostic devices in
an effort to cut down overall healthcare costs relating to the biomarker development itself.

Frost & Sullivan expects that many in vitro diagnostics (IVD) companies will evolve and
reorganize their goals (better planning for R&D biomarker development costs) in Europe
given the recent change in the IVD directive that will govern the companion diagnostic
landscape from 2014 onwards.

A comparative analysis of various regulatory pathways for companion diagnostic tests
reveal that, the United States, China, Japan, and Australia are well regulated markets with
established pathways. As of 2013, Europe was the least regulated and Russia, India, and
Brazil exhibit a similarity for moderately regulated markets.

Certain countries had a well established health authority to review products before their
acceptance in the market, while other countries did not have a proper mechanism in place.
This variation was because of the classification of companion diagnostic tests into a risk-based classification.

A thorough understanding of various regulatory pathways reveal that every system has its
own pros and cons; understanding this to the utmost detail will help manufacturers to
allocate costs in a much more reasonable manner.

Qiagen, Dako, Roche, and bioMérieux have been successful with many products. They
also have a strong pipeline of tests for oncology and other emerging areas such as
infectious disease, central nervous system (CNS), and cardiovascular disease areas.
These companies have a broad understanding of various regulatory hurdles that challenge
market entry strategies. Understanding regional barriers is also important to be able to
choose an appropriate commercialization/biomarker development partner.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers
2017 Europe Hematology and Flow Cytometry Market: Sales and Volume Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation Review, Emerging Technologies

2017 Europe Hematology and Flow Cytometry Market: Sales and Volume Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation Review, Emerging Technologies

  • $ 29500
  • Industry report
  • February 2017
  • by Venture Planning Group

This new 31-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test. The survey is designed to help current suppliers and potential market entrants ...

2017-2021 World Clinical Chemistry and Immunodiagnostic Markets: Global Opportunities and Growth Strategies for Instrument and Reagent Suppliers

2017-2021 World Clinical Chemistry and Immunodiagnostic Markets: Global Opportunities and Growth Strategies for Instrument and Reagent Suppliers

  • $ 23500
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $37,500.  DataPack (test volumes, sales forecasts, supplier shares) $23,500.VPGMarketReserch.com's new report is a seven-country strategic analysis of major business opportunities emerging ...

Immunodiagnostics 2021: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts for 100 Tests--Clinical Chemistry, Drugs of Abuse, Endocrine Function, Immunoproteins, Special Chemistry, Therapeutic Drug Monitoring (TDM), Tumor Markers

Immunodiagnostics 2021: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts for 100 Tests--Clinical Chemistry, Drugs of Abuse, Endocrine Function, Immunoproteins, Special Chemistry, Therapeutic Drug Monitoring (TDM), Tumor Markers

  • $ 23500
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report PDF $37,500, DataPack (500 tables) $23,500. The report is available by geographic region, country, section, market segment, test category, and individual assay. VPGMarketResearch.com new ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.